Efficacy, safety, pharmacokinetics and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: A phase II study.
Clin Cancer Res. 2013;19(6):1557-66 - PMID: 23362324 - PMCID: PMC3609423 - DOI: 10.1158/1078-0432.CCR-12-3041
Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948).
Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer.
Oncologist. 2012;17(2):212-9 - PMID: 22302227 - PMCID: PMC3286170 - DOI: 10.1634/theoncologist.2011-0321
Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer.
Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide.
J Neurooncol. 2011;103(2):325-32 - PMID: 20821342 - PMCID: PMC4090923 - DOI: 10.1007/s11060-010-0390-7
Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma.
Clin Ovarian Cancer Other Gynecol Malig. 2011;4(1):26-33 - PMID: 21833345 - PMCID: PMC3151740 - DOI: 10.1016/j.cloc.2011.04.003
Glioblastoma recurrence after cediranib therapy in patients: lack of rebound revascularization as mode of escape.
Cancer Res. 2011;71(1):19-28 - PMID: 21199795 - PMCID: PMC3074948 - DOI: 10.1158/0008-5472.CAN-10-2602
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
J Clin Oncol. 2010;28(17):2817-23 - PMID: 20458050 - PMCID: PMC2903316 - DOI: 10.1200/JCO.2009.26.3988
Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer.
Oncologist. 2010;15(6):577-83 - PMID: 20484123 - PMCID: PMC3061828 - DOI: 10.1634/theoncologist.2010-0029
A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer.
Oncologist. 2010;15(8):845-51 - PMID: 20667969 - PMCID: PMC3078712 - DOI: 10.1634/theoncologist.2010-0030
A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients.
Cancer Res. 2009;69(13):5296-300 - PMID: 19549889 - PMCID: PMC2824172 - DOI: 10.1158/0008-5472.CAN-09-0814
11